Bundamedik Tbk PT (BMHS) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.58x

Bundamedik Tbk PT (BMHS) has a Cash Flow Reinvestment Rate of 0.58x as of December 2025, reinvesting Rp116.26 Billion (capex Rp116.26 Billion ) from operating cash flow of Rp199.64 Billion. Check BMHS operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.58x
(Capex + Investments) / Operating CF

Total Reinvested

Rp116.26 Billion
Capex + Investments

Operating Cash Flow

Rp199.64 Billion
IDR

Capital Expenditures

Rp116.26 Billion
IDR

Bundamedik Tbk PT Cash Flow Reinvestment Rate (2018–2025)

Historical reinvestment intensity for Bundamedik Tbk PT across 8 annual periods. Explore BMHS operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Bundamedik Tbk PT (2018–2025)

Year-by-year capital reinvestment analysis for Bundamedik Tbk PT. For live market cap and broader valuation context, see BMHS market cap overview.

Year Reinvestment Rate Total Reinvested (IDR) Operating CF Capex YoY Change
2025 0.87x Rp218.91 Billion Rp250.62 Billion Rp218.91 Billion ▼ -93.8%
2024 14.16x Rp481.32 Billion Rp33.98 Billion Rp236.03 Billion ▲ +72.8%
2023 8.20x Rp421.57 Billion Rp51.44 Billion Rp209.35 Billion ▲ +163.1%
2022 3.12x Rp739.76 Billion Rp237.47 Billion Rp301.73 Billion ▲ +336.2%
2021 0.71x Rp249.57 Billion Rp349.44 Billion Rp228.08 Billion ▲ +91.2%
2020 0.37x Rp71.10 Billion Rp190.36 Billion Rp49.61 Billion ▼ -60.2%
2019 0.94x Rp84.26 Billion Rp89.72 Billion Rp72.50 Billion ▼ -73.7%
2018 3.57x Rp156.54 Billion Rp43.79 Billion Rp156.54 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow